Your details appear on your Certificate of Completion and are stored only on this device.
What to look for before glucose becomes abnormal - clinical and laboratory markers.
Standard screening for type 2 diabetes relies on fasting glucose and HbA1c - but these only become abnormal after years of compensatory hyperinsulinemia. By the time glucose is elevated, significant metabolic damage has already occurred. The signs below appear much earlier and give you and your physician the opportunity to intervene when dietary change is most effective.
| Sign | What It Looks Like | Why It Happens | Next Step |
|---|---|---|---|
| Acanthosis Nigricans | Velvety, darkened skin in skin folds - neck, armpits, groin, elbows. Often mistaken for poor hygiene. | Strongly associated with hyperinsulinemia. Insulin stimulates keratinocyte and fibroblast proliferation via IGF-1 receptors. | Document location and extent. Order fasting insulin and HOMA-IR. |
| Central Adiposity | Excess fat stored around the abdomen (waist circumference >35 in women, >40 in men) rather than hips and thighs. | Visceral fat is metabolically active, secreting inflammatory cytokines and free fatty acids that worsen insulin resistance. | Measure waist circumference at every visit. Waist-to-height ratio >0.5 is a more sensitive marker. |
| Skin Tags (Acrochordons) | Small, soft, flesh-colored growths on the neck, armpits, or groin. Multiple skin tags are a clinical marker of hyperinsulinemia. | Same mechanism as acanthosis nigricans - insulin-driven proliferation of skin cells via IGF-1 receptors. | Count and document. Presence of >3 skin tags warrants metabolic screening. |
| Fatigue After Meals | Significant drowsiness or energy crash 1–2 hours after eating, especially after carbohydrate-rich meals. | Reflects exaggerated postprandial insulin response followed by reactive hypoglycemia or cellular energy dysregulation. | Ask about post-meal energy at every visit. Consider CGM to document postprandial glucose and insulin patterns. |
| Polycystic Ovary Syndrome (PCOS) | Irregular periods, excess androgens, and polycystic ovaries. Insulin resistance is present in ~70% of PCOS cases. | Hyperinsulinemia stimulates ovarian androgen production and suppresses SHBG, driving the hormonal features of PCOS. | Screen all PCOS patients for insulin resistance with fasting insulin and HOMA-IR, not just glucose. |
| Marker | Optimal Range | Why It Matters | Clinical Action |
|---|---|---|---|
| Fasting Insulin | 2–5 mIU/L | Joseph Kraft's data on 14,000+ patients showed that most people with normal fasting glucose already have abnormal insulin patterns. Fasting insulin is the earliest metabolic marker. | Order fasting insulin alongside fasting glucose. Optimal range: 2–5 mIU/L. Above 10 mIU/L is significant hyperinsulinemia. |
| HOMA-IR | < 1.5 (optimal < 1.0) | HOMA-IR quantifies the degree of insulin resistance from a single fasting blood draw. It predicts type 2 diabetes years before HbA1c rises. | Calculate HOMA-IR whenever fasting glucose and insulin are ordered. Share the number with the patient - it is highly motivating. |
| Triglycerides | < 100 mg/dL | Insulin normally suppresses hepatic VLDL production. When cells become insulin resistant, the liver continues producing triglycerides despite elevated insulin. | Use 100 mg/dL as the optimal cutoff, not 150. Elevated TG in the context of low HDL is a strong metabolic risk signal. |
| HDL | > 50 (W) / > 40 (M) | Elevated triglycerides drive CETP-mediated exchange, depleting HDL particles. Low HDL reflects dysfunctional lipid metabolism, not dietary fat intake. | Evaluate TG:HDL ratio. A ratio above 3.0 (mg/dL units) is a strong predictor of insulin resistance and small dense LDL. |
| TG:HDL Ratio | < 2.0 | A TG:HDL ratio above 3.0 correlates strongly with hyperinsulinemia, small dense LDL, and cardiovascular risk - often better than LDL-C alone. | Calculate from the standard lipid panel. Share with patients as a simple, actionable number. Goal: below 2.0. |
| Uric Acid | < 5.5 mg/dL | Fructose metabolism generates uric acid as a byproduct. Uric acid inhibits endothelial nitric oxide, raising blood pressure and impairing insulin signaling. | Order uric acid in all metabolic screening panels. Optimal: below 5.5 mg/dL. Elevated uric acid often precedes gout, hypertension, and T2D. |
| hsCRP | < 1.0 mg/L | Visceral fat secretes IL-6, which drives hepatic CRP production. Chronic low-grade inflammation amplifies insulin resistance through NF-κB pathways. | Use hsCRP as a metabolic inflammation marker, not just a cardiovascular risk marker. Goal: below 1.0 mg/L. |